类似的还有用胸腺肽、白介素、干扰素来“增强免疫功能”,认为可以对治疗新冠感染有帮助,这也是一种误解。
以胸腺肽为例,它是一种可以促进原本安静地呆在胸腺里的“前T细胞(T细胞的前体)”转化为T细胞,并进一步分化成熟为不同功能的T细胞亚群的药物。显然,对于某些会导致T细胞减少的相关疾病来说,胸腺肽是对症的。
[3] Marcec R,Dodig VM,Radanovic I,Likic R. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2022;32(6):e2397. doi:10.1002/rmv.2397
[4] Snow TAC,Saleem N,Ambler G,et al. Convalescent plasma for COVID-19: a meta-analysis,trial sequential analysis,and meta-regression. Br J Anaesth. 2021;127(6):834-844. doi:10.1016/j.bja.2021.07.033
[5] ITAC (INSIGHT 013) Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind,placebo-controlled,phase 3,randomised trial. Lancet. 2022;399(10324):530-540. doi:10.1016/S0140-6736(22)00101-5